GT
MDGL icon

Glenmede Trust’s Madrigal Pharmaceuticals MDGL Stock Holding History

Glenmede Trust’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$404K Buy
772
+81
+12% +$38.7K ﹤0.01% 1041
2025
Q4 		$402K Buy
+691
New +$353K ﹤0.01% 1019
2024
Q1 		– Sell
-1,066
Closed -$247K – 1371
2023
Q4 		$247K Sell
1,066
-501
-32% -$87.7K ﹤0.01% 1089
2023
Q3 		$229K Buy
1,567
+544
+53% +$102K ﹤0.01% 1068
2023
Q2 		$248K Hold
1,023
– – ﹤0.01% 1040
2023
Q1 		$248K Buy
+1,023
New +$279K ﹤0.01% 1045
2019
Q1 		– Sell
-68
Closed -$7 – 3130
2018
Q4 		$7 Buy
+68
New +$10.5K ﹤0.01% 2429

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return